Search results for "ALDH1A1"

showing 2 items of 2 documents

WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer

2019

Triple-negative breast cancers (TNBCs) are characterized by a poor prognosis and lack of targeted treatments, and thus, new therapeutic strategies are urgently needed. Inhibitors against programmed death-1 (PD-1)/PD-1 ligand (PD-L1) have shown significant efficacy in various solid cancers, but their activity against TNBCs remains limited. Here, we report that human TNBCs molecularly stratified for high levels of PD-L1 (PD-L1High) showed significantly enriched expression of immune and cancer stemness pathways compared with those with low PD-L1 expression (PD-L1Low). In addition, the PD-L1High cases were significantly associated with a high stemness score (SSHigh) signature. TNBC cell lines g…

0301 basic medicineCell biologyCancer ResearchTriple Negative Breast NeoplasmImmunologyDown-RegulationTriple Negative Breast NeoplasmsArticleB7-H1 Antigen03 medical and health sciences0302 clinical medicineImmune systemStem CellCell Line TumorBiomarkers TumorGeneticsmedicineAnimalsHumansWnt Signaling PathwayMolecular BiologyTriple-negative breast cancerMice Inbred BALB CbiologyAnimalStem CellsCD44Wnt signaling pathwayCancerAldehyde Dehydrogenasemedicine.diseaseHyaluronan ReceptorUp-RegulationALDH1A1Hyaluronan Receptors030104 developmental biology030220 oncology & carcinogenesisbiology.proteinCancer researchFemaleStem cellB7-H1 AntigenHumanOncogene
researchProduct

Dual disruption of aldehyde dehydrogenases 1 and 3 promotes functional changes in the glutathione redox system and enhances chemosensitivity in nonsm…

2020

AbstractAldehyde dehydrogenases (ALDHs) are multifunctional enzymes that oxidize diverse endogenous and exogenous aldehydes. We conducted a meta-analysis based on The Cancer Genome Atlas and Gene Expression Omnibus data and detected genetic alterations in ALDH1A1, ALDH1A3, or ALDH3A1, 86% of which were gene amplification or mRNA upregulation, in 31% of nonsmall cell lung cancers (NSCLCs). The expression of these isoenzymes impacted chemoresistance and shortened survival times in patients. We hypothesized that these enzymes provide an oxidative advantage for the persistence of NSCLC. To test this hypothesis, we used genetic and pharmacological approaches with DIMATE, an irreversible inhibito…

Male0301 basic medicineCancer ResearchLung NeoplasmsCell- och molekylärbiologiCellAldehyde dehydrogenaseKaplan-Meier EstimateMicechemistry.chemical_compound0302 clinical medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsCytotoxicityMiddle AgedAldehyde OxidoreductasesGlutathioneCancer metabolismUp-Regulation3. Good healthCancer therapeutic resistancemedicine.anatomical_structureAlkynes030220 oncology & carcinogenesisFemale[SDV.CAN]Life Sciences [q-bio]/CancerBiologyIsozymeAldehyde Dehydrogenase 1 FamilyArticle03 medical and health sciencesTargeted therapiesDownregulation and upregulationCell Line TumorGeneticsmedicineAnimalsHumansSulfhydryl CompoundsLung cancerMolecular BiologyAgedCancer och onkologiGene AmplificationRetinal DehydrogenaseGlutathioneAldehyde Dehydrogenasemedicine.diseaseXenograft Model Antitumor AssaysALDH1A1030104 developmental biologychemistryDrug Resistance NeoplasmCancer and Oncologybiology.proteinCancer researchCisplatinReactive Oxygen SpeciesCell and Molecular Biologynonsmall cell lung cancer
researchProduct